Phase 1 N=72 Assessment of the Human Systemic Absorption of Sunscreen Ingredients
Systemic Exposure to Sunscreen Ingredients
Primary: Avobenzone Maximum Concentration — 1.8; 4.3; 4.0; 3.4 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
Skin Cancer
Primary: DNA Damage Level by Cyclobutane Pyrimidine Dimer (CPD) Measurement — 2.48; 2.18; 2.64; 1.14 Optical Density Units — p=0.003
Phase 2 N=16 Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Idiopathic Solar Urticaria
Primary: Assessment of the Minimal Urticaria Dose (MUD) on Each Test Site, After Application of the Test Products — 4.33; 3.93; 3.80; 3.67 Photodermatosis Protection Factor
Phase 3 N=10 Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)
Sun Protection
Primary: Determination of Sunscreen Protection Factor (SPF) — 14.72; 15.00 Score on a scale
N/A N=8 A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations
Sunscreening Agents
Primary: Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values — 33.1; 35.2; 35.2; 45.2 Ratio
N/A N=164 UV Exposure Assessed With Wearable Sensor and Sun Protection
Sunburn, Erythema · Sun Protection
Primary: Acceptability of Wearing UV Sensor and Receiving Text Messages — 22; 39.1; 40.1; 40.6 score on a scale — p=<0.01
Early Phase 1 N=70 Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
Skin Cancer
Primary: Number of Days the Subjects Are Adherent to Using Sunscreen — 12.6; 23.6 days
N/A N=13 Clinical Study to Evaluate the Sun Protection Factor (SPF) of Three Sunscreen Products
Sunscreening Agents
Primary: Arithmetic Mean SPF Values — 29.2; 16.4; 28.2; 16.4 Ratio
N/A N=15 Clinical Study to Evaluate the 80-Minute Water Resistant Sun Protection Factor (SPF) of Sunscreen Products
Sunscreening Agents
Primary: Arithmetic Mean SPF Values
N/A N=11 Clinical Study to Evaluate the Sun Protection Factor (SPF) of Sunscreen Products
Sunscreening Agents
Primary: Arithmetic Mean SPF Values — 13.9; 16.1; 14.3; 15.8 Ratio
Phase 2 N=100 Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
Patients at Risk for Melanoma
Primary: UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi — 94.6; 96.2; 33.6; 33.1 percentage of 8-OG expression in nevi — p=.65
N/A N=37 A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion
Skin Care
Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants
N/A N=368 Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Melanoma (Skin)
Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale
N/A N=26 Determination of the Sun Protection Factor (SPF) of a Cosmetic Daily De-fence Skin Cream
Sunscreening Agents
Primary: Arithmetic Mean of Individual Sun Protection Factor (SPFi) Value — 19.4; 14.0 Ratio (unit less)
N/A N=543 Virtual Sun Safe Workplaces Ph II (SSW Works)
Skin Cancer · Occupational Exposure
Primary: Change From Baseline Employee Sun Protection Practices at 1 Year — 3.55; 3.30; 3.71; 3.46 score on a scale
Phase 4 N=128 Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
Skin Irritation
Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants
N/A N=7 Photocil (Topical) for the Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Pruritus Events in Last 30 Days — 7.4; 1.9 Events
Phase 2 N=10 Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers
Aging · Skin Abnormalities
Primary: Change in Common Deletion (CD) Value in DNA of Skin Biopsy Sample — -84; 217 percent change
Phase 2 N=156 Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
Other Benign Neoplasm of Skin, Unspecified
Primary: Changes in Putrescine Over 3 Months — 0.03; 1.45; 0.2 nmol/g skin
Phase 3 N=32 Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
Dermatitis, Phototoxic
Primary: Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score — 77; 10; 85; 2 Test site
Phase 3 N=137 Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants
Dermatitis, Photoallergic
Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site
N/A N=15 Photocil (Topical) for the Treatment of Vitiligo
Vitiligo
Primary: Percent Repigmentation — 48.5; 2.5 Percent Repigmentation
N/A N=94 Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection
Melanoma
Primary: Number of Participants Interviewed on UVR Protection Behaviors. — 25; 0; 0; 59 Participants
Phase 2 N=83 Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses
Precancerous Condition
Primary: Change in Histopathology Score of Sun Damaged Skin by Treatment Group — 0.4; -0.1; 0.1 units on a scale — p=0.10
N/A N=38 Sun Protection and Tanning Awareness in Rural Schools
Melanoma · Adolescents
Primary: Sun Protection Index Scores - Weekday — .179 score on a scale
Phase 2 N=191 Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Breast Carcinoma · Pain · Radiation-Induced Dermatitis
Primary: Mean Radiation Dermatitis Severity (RDS) Score. Range: 0 (no Dermatitis) - 4 (Violaceous Erythema With Diffuse Desquamation Occurring in Sheets; Patchy Crusting…
N/A N=41 Using Physical Tracking to Predict Sunburn
Prevention
Primary: Prevalence of Sun Protection Practices — 0.30; 0.43; 0.35; 0.41 proportion of practices/day
N/A N=54 Skin Care Behaviors Among Melanoma Survivors and Their Families
Melanoma
Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants
N/A N=14 Sun Protection Factor (SPF) Determination of Two Sunscreen-Containing Lip Balms
Sunscreening Agents
Primary: Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values — 17.3; 17.9; 19.3; 18.4 Ratio
Phase 4 N=954 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Carcinoma, Basal Cell · Carcinoma, Squamous Cell · Skin Neoplasms
Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93